Financial Data and Key Metrics Changes - In Q4 2025, Anika generated total revenue of $30.6 million, flat year-over-year, consistent with revised full-year expectations [16] - Commercial channel revenue grew 22% to $13.3 million, driven by strong international execution and continued momentum in Integrity [16] - GAAP gross margin increased to 63% from 56% in the prior year, reflecting higher revenue from international OA pain sales and improved manufacturing productivity [18] - For the full year 2025, total revenue was $112.8 million, a decline of 6% compared to the prior year, with commercial channel revenue up 15% to $48.4 million [20][21] Business Line Data and Key Metrics Changes - International OA pain management revenue increased 28% in Q4 and 12% for the full year, reflecting strong execution and market share gains [8][20] - Integrity revenue more than doubled to approximately $6 million in 2025, marking its seventh consecutive quarter of growth [9][20] - OEM channel revenue declined 12% in Q4 and 17% for the full year, primarily due to pricing pressures in the U.S. market [9][21] Market Data and Key Metrics Changes - The international OA pain management portfolio, including Monovisc and Cingal, delivered strong growth, with significant share gains across multiple regions [8][20] - Hyalofast continued to gain traction outside the U.S., benefiting from its ease of use and differentiation [8] Company Strategy and Development Direction - The company has three strategic priorities: revenue growth through the commercial channel, advancing the HA-based innovation pipeline, and improving operational execution [6][7] - Focus on expanding the international OA pain portfolio and scaling Integrity as a differentiated regenerative platform [6] - The company aims to strengthen operational execution through improved manufacturing productivity and a streamlined organizational design [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver improved performance and long-term value, entering 2026 with clarity and momentum [28] - The company expects full-year revenue for 2026 to be between $114 million and $122.5 million, reflecting continued momentum in the commercial channel [26] - Adjusted EBITDA is expected to be 5% to 10% of revenue, supported by growth in the commercial channel and cost reduction actions [27] Other Important Information - The company ended 2025 with $57.5 million in cash and no debt, providing a strong liquidity position [23] - A $15 million stock repurchase plan was initiated in November 2025, with $10.7 million already purchased [23] Q&A Session Summary Question: Contribution from U.S. Hyalofast in 2027 - Management indicated that approximately $3 million of anticipated revenue for Hyalofast in 2027 remains contingent upon U.S. approval [30] Question: Normalized gross margin expectations for 2026 - Management expects normalized gross margins to be in the high 50s, acknowledging that the current quarter's margins may not be sustainable [31][32] Question: Free cash flow expectations for 2026 - Management anticipates free cash flow for 2026 to be somewhat in line with 2025 levels, considering restructuring elements [34][35] Question: Dynamics of international OA pain performance - Management noted sustained market share gains and growth in new markets, with no single market driving top-line growth [36] Question: Improvement in OEM channel despite pricing headwinds - Management attributed the sequential improvement in the OEM channel to volume and end-user demand, particularly for Monovisc [40] Question: Timeline for Cingal's NDA filing - Management stated that the NDA filing timeline will depend on the enrollment of the bioequivalence study, which is currently ongoing [42] Question: Revenue growth expectations for Integrity in 2026 - Management expects strong double-digit growth for Integrity in 2026, although not at the same variance percentage as in 2025 [44] Question: Capital allocation priorities - Management emphasized investments in manufacturing operations and U.S. sales channels as top priorities, with potential for future evaluations of M&A opportunities [53][55]